1037543-27-3 Usage
Uses
Used in Pharmaceutical Industry:
2,4-Dichloro-6-methoxymethyl-pyrimidine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the molecular structures of potential drugs. Its unique functional groups allow for further chemical reactions that can lead to the development of new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4-Dichloro-6-methoxymethyl-pyrimidine is utilized as an intermediate in the production of pesticides and other crop protection agents. Its chemical properties make it suitable for the creation of compounds that can protect crops from pests and diseases.
Used in Antiviral and Antimicrobial Research:
2,4-Dichloro-6-methoxymethyl-pyrimidine is used as a subject of study in scientific research for its potential antiviral and antimicrobial properties. Its unique structure may offer new avenues for the development of treatments against viral and bacterial infections.
Overall, 2,4-Dichloro-6-methoxymethyl-pyrimidine's applications are diverse, spanning across different fields that can benefit from its chemical characteristics and potential therapeutic effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1037543-27-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,7,5,4 and 3 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1037543-27:
(9*1)+(8*0)+(7*3)+(6*7)+(5*5)+(4*4)+(3*3)+(2*2)+(1*7)=133
133 % 10 = 3
So 1037543-27-3 is a valid CAS Registry Number.
1037543-27-3Relevant articles and documents
AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS
-
Paragraph 01220; 01224-01226, (2017/11/10)
The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
